A successful vaccine trial in West Africa promises long-term, low-cost protection against meningitis. The Meningitis Vaccine Project (MVP) has released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine - expected to sell initially for 40 US cents a dose -will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region.
展开▼
